Lyell Immunopharma, Inc.
LYELDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How LYEL's past catalysts played out
rondecabtagene autoleucel
Large B-cell Lymphoma
LYL314
Relapsed Non-Hodgkin Lymphoma
LYL273
Colorectal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
rondecabtagene autoleucel | Phase 3 | Large B-cell Lymphoma | - | - |
LYL314 | Phase 2 | Relapsed Non-Hodgkin Lymphoma | - | - |
LYL273 | Phase 2 | Colorectal Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Lyell Immunopharma, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Lyell Immunopharma, Inc.'s (LYEL) pipeline across Phase 3, Phase 2. Its lead program is rondecabtagene autoleucel (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Lyell Immunopharma, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Lyell Immunopharma, Inc. (LYEL) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LYEL biotech catalysts?→
Add LYEL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lyell Immunopharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.